Please login to the form below

Not currently logged in
Email:
Password:

Lartruvo

This page shows the latest Lartruvo news and features for those working in and with pharma, biotech and healthcare.

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo

Lilly bags EU approval for cancer treatment Lartruvo. Licensed for use with doxorubicin for soft tissue sarcoma patients. ... Until then, Lartruvo will be subject to an annual safety review by the CHMP.

Latest news

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Lilly snags first approval for sarcoma drug Lartruvo. Granted accelerated approval by the FDA becoming first front-line STS therapy for 40 years. ... Eli Lilly has picked up its first green light for its soft tissue sarcoma (STS) therapy Lartruvo, ending

  • Lilly closes on first approval for sarcoma drug Lartruvo Lilly closes on first approval for sarcoma drug Lartruvo

    Lilly closes on first approval for sarcoma drug Lartruvo. Orphan drug improved patient survival time by almost 12 months in phase II trial. ... It is thought that by binding to the receptor Lartruvo can slow down tumour growth.

More from news
Approximately 3 fully matching, plus 0 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy approvals are Lartruvo (for the treatment of soft tissue sarcoma, approved in the EU and US), Rubraca (for the treatment of ovarian cancer, only approved in the US),

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
huumun formerly PharmiWeb Solutions

huumun, is a digital transformation business. For us, digital transformation means using digital technologies, not just to turn an existing...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics